Skip to main navigation Skip to search Skip to main content

Potential role of cannabidiol for seizure control in a patient with recurrent glioma

Research output: Contribution to journalArticlepeer-review

7 Citations (Scopus)

Abstract

Glioma-related epilepsy significantly impact on patients’ quality of life, and can often be difficult to treat. Seizures cause significant morbidity for example neurocognitive deterioration, which may result from seizures themselves or due to adverse effects from antiepileptic drugs. Management of tumour with surgery, radiotherapy and chemotherapy may contribute to seizure control, but tumour related epilepsy is often refractory despite adequate treatment with standard anti-epileptic medications. Given the increasing interest in medicinal cannabis (or cannabidiol or CBD) as an anti-epileptic drug, CBD may help with seizure control in glioma patients with treatment-refractory seizures. Here we present a case of a young lady with recurrent glioma who had refractory seizures despite multiple anti-epileptic agents, who had significant benefit with CBD.

Original languageEnglish
Pages (from-to)275-276
Number of pages2
JournalJournal of Clinical Neuroscience
Volume71
DOIs
Publication statusPublished - Jan 2020

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

  1. SDG 3 - Good Health and Well-being
    SDG 3 Good Health and Well-being

Keywords

  • Anti-epileptic
  • Cannabidiol
  • Epilepsy
  • Glioma
  • Treatment-refractory

Fingerprint

Dive into the research topics of 'Potential role of cannabidiol for seizure control in a patient with recurrent glioma'. Together they form a unique fingerprint.

Cite this